logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > China Stock

Chengdu Galaxy Magnets (300127.SZ): Galaxy Group has cumulatively reduced its holdings of the company by 3.1999 million shares.

date
20:52 06/03/2025
avatar
GMT Eight
Galaxy Magnets (300127.SZ) released an announcement that as of March 6, 2025, the Galaxy Group has cumulatively reduced its holdings...
Chengdu Galaxy Magnets (300127.SZ) announced that as of March 6, 2025, Galaxy Group has cumulatively reduced its holdings of the company's shares by 3.1999 million shares. The current reduction plan has been completed.
Related Articles
China Stock
Shanghai Shyndec Pharmaceutical's subsidiary obtains the drug registration certificate for Tafurinol eye drops.
China Stock
Tasly Pharmaceutical Group's subsidiary has obtained the registration certificate for bosentan dispersible tablets.
China Stock
Huiyu Pharmaceutical (688553.SH) subsidiary's clinical trial application for injection HY07121 (subcutaneous injection) has been accepted.
Shanghai Shyndec Pharmaceutical's subsidiary obtains the drug registration certificate for Tafurinol eye drops.
China Stock
Tasly Pharmaceutical Group's subsidiary has obtained the registration certificate for bosentan dispersible tablets.
China Stock
Huiyu Pharmaceutical (688553.SH) subsidiary's clinical trial application for injection HY07121 (subcutaneous injection) has been accepted.
China Stock
RECOMMEND
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
icon
10/06/2026
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
icon
10/06/2026
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
icon
10/06/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.